These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31640478)

  • 21. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
    Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M
    Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daprodustat prevents cyclosporine-A-mediated anemia and peritubular capillary loss.
    Labes R; Brinkmann L; Kulow VA; Roegner K; Mathia S; Balcerek B; Persson PB; Rosenberger C; Fähling M
    Kidney Int; 2022 Oct; 102(4):750-765. PubMed ID: 35643373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis.
    Xie D; Wang J; Wu X; Li M
    Int Urol Nephrol; 2018 Dec; 50(12):2201-2206. PubMed ID: 30073615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors induce autophagy and have a protective effect in an in-vitro ischaemia model.
    Singh A; Wilson JW; Schofield CJ; Chen R
    Sci Rep; 2020 Jan; 10(1):1597. PubMed ID: 32005890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Randomized, Placebo- and Positive-Controlled, Single-Dose, Crossover Thorough QT/QTc Study Assessing the Effect of Daprodustat on Cardiac Repolarization in Healthy Subjects.
    Caltabiano S; Collins J; Serbest G; Morgan L; Smith DA; Ravindranath R; Cobitz AR
    Clin Pharmacol Drug Dev; 2017 Nov; 6(6):627-640. PubMed ID: 28419747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic Function.
    Mahar KM; Shaddinger BC; Ramanjineyulu B; Andrews S; Caltabiano S; Lindsay AC; Cobitz AR
    Clin Pharmacol Drug Dev; 2022 May; 11(5):562-575. PubMed ID: 35355447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors.
    Wu Y; Jiang Z; You Q; Zhang X
    Bioorg Med Chem; 2017 Aug; 25(15):3891-3899. PubMed ID: 28625716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of prolyl-hydroxylase inhibition and chronic intermittent hypoxia on synaptic transmission and plasticity in the rat CA1 and dentate gyrus.
    Wall AM; Corcoran AE; O'Halloran KD; O'Connor JJ
    Neurobiol Dis; 2014 Feb; 62():8-17. PubMed ID: 24055213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
    Wu Y; Jiang Z; Li Z; Gu J; You Q; Zhang X
    J Med Chem; 2018 Jun; 61(12):5332-5349. PubMed ID: 29856623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Topical Daprodustat in Healthy Volunteers and in Patients With Diabetic Foot Ulcers.
    Olson E; Mahar KM; Morgan L; Fillmore C; Holland C; Lavery L
    Clin Pharmacol Drug Dev; 2019 Aug; 8(6):765-778. PubMed ID: 30720931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigation of the human metabolism and disposition of the prolyl hydrolase inhibitor daprodustat using IV microtracer with Entero-Test bile string.
    Tai G; Xia F; Chen C; Pereira A; Pirhalla J; Miao X; Young G; Beaumont C; Chen L
    Pharmacol Res Perspect; 2023 Dec; 11(6):e1145. PubMed ID: 37885335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The stabilization of hypoxia inducible factor modulates differentiation status and inhibits the proliferation of mouse embryonic stem cells.
    Binó L; Kučera J; Štefková K; Švihálková Šindlerová L; Lánová M; Kudová J; Kubala L; Pacherník J
    Chem Biol Interact; 2016 Jan; 244():204-14. PubMed ID: 26723917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure.
    Caltabiano S; Cizman B; Burns O; Mahar KM; Johnson BM; Ramanjineyulu B; Serbest G; Cobitz AR
    Clin Kidney J; 2019 Oct; 12(5):693-701. PubMed ID: 31583094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of prolyl hydroxylase domain-containing protein on hypertension/renal injury induced by high salt diet and nitric oxide withdrawal.
    Dallatu MK; Choi M; Oyekan AO
    J Hypertens; 2013 Oct; 31(10):2043-9. PubMed ID: 23811999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease.
    Ishii T; Tanaka T; Nangaku M
    Ther Clin Risk Manag; 2021; 17():155-163. PubMed ID: 33628028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating the safety and efficacy of daprodustat for anemia of chronic kidney disease: a meta-analysis of randomized clinical trials.
    Fatima K; Ahmed W; Fatimi AS; Mahmud O; Mahar MU; Ali A; Aamir SR; Nasim MT; Islam MB; Maniya MT; Azim D; Marsia S; Almas T
    Eur J Clin Pharmacol; 2022 Dec; 78(12):1867-1875. PubMed ID: 36195739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TP0463518, a novel inhibitor for hypoxia-inducible factor prolyl hydroxylases, increases erythropoietin in rodents and monkeys with a good pharmacokinetics-pharmacodynamics correlation.
    Kato S; Takayama N; Takano H; Koretsune H; Koizumi C; Kunioka EI; Uchida S; Takahashi T; Yamamoto K
    Eur J Pharmacol; 2018 Nov; 838():138-144. PubMed ID: 30179610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein Hydroxylation by Hypoxia-Inducible Factor (HIF) Hydroxylases: Unique or Ubiquitous?
    Strowitzki MJ; Cummins EP; Taylor CT
    Cells; 2019 Apr; 8(5):. PubMed ID: 31035491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease.
    Hasegawa S; Tanaka T; Saito T; Fukui K; Wakashima T; Susaki EA; Ueda HR; Nangaku M
    Kidney Int; 2020 May; 97(5):934-950. PubMed ID: 32171449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.